Relationship Between Antipsychotic Use and Cholesterol Levels in a Retrospective Chart Review of an Adult Autism Clinic Patient Population

Individuals with autism spectrum disorder (ASD) experience a high prevalence of metabolic and gastrointestinal (GI) comorbidities. Antipsychotics are commonly prescribed for adults with ASD. Our study investigated the effect of antipsychotic medication on metabolic and GI comorbidities, as well as effects across age, in an adult ASD population. We retrospectively analyzed 279 charts from patients with ASD, ages 16–62 (mean = 27.97, SD = 8.89, 18.3% female). Data abstracted included demographic information, medications taken, GI and metabolic comorbidities, and recent values for body mass index (BMI), triglycerides, and total cholesterol. Participants were separated into two groups based on antipsychotic use. Between-group differences were calculated for the prevalence of GI comorbidities and mean values for BMI, triglycerides, and total cholesterol. Lastly, binary correlations were calculated for age and total cholesterol as well as triglycerides, and age and BMI. No significant difference was found between the prevalence of GI comorbidities for the two groups. For metabolic factors, no significant difference was found in the mean BMI, triglycerides, or total cholesterol. Binary correlation analysis also revealed no significant correlation between age and BMI or triglycerides for patients in either group. A significant correlation was found between age and total cholesterol for patients both taking and not taking antipsychotics. Despite approximately one in three patients in this study taking an antipsychotic medication, no significant differences in GI or metabolic comorbidities were found. However, cholesterol increased with age regardless of the presence or absence of antipsychotics. Future research is needed to better understand the long-term effects of antipsychotics on adults with ASD and metabolic monitoring in those not on antipsychotics.